Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 2/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.40 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16739391 | 0.83 | TERT (0.49) | TERTAPPNPC1RAB9ARXFP1 | |
| SCHEMBL18226915 | 0.81 | TERT (0.46) | TERTAPPNPC1RAB9ARXFP1 | |
| SCHEMBL18227018 | 0.75 | HRH4 (0.48) | TERTAPPMAPTKDM4EALDH1A1 | |
| SCHEMBL16739382 | 0.74 | EGFR (0.48) | TERTAPPNPC1RAB9ARXFP1 | |
| SCHEMBL18227073 | 0.73 | TERT (0.47) | TERTAPPNPC1RAB9ARXFP1 | |
| SCHEMBL18227144 | 0.71 | TERT (0.49) | TERTAPPNPC1RAB9APSMB5 | |
| SCHEMBL18227070 | 0.71 | TERT (0.49) | TERTAPPNPC1RAB9AMAPT | |
| SCHEMBL16739387 | 0.69 | KDR (0.40) | NPC1RAB9ARXFP1MAPTKDM4E | |
| SCHEMBL16739385 | 0.69 | MAPT (0.38) | TERTAPPNPC1RAB9ARXFP1 | |
| Acridine Orange SCHEMBL297155 | 0.68 | TERT (1.00) | TERTAPPNPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873670-B2 | Arylquinoline and analog compounds and use thereof to treat cancer | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160332971-A1 | ARYLQUINOLINE, ARYLQUINOLONE AND ARYLTHIOQUINOLONE DERIVATIVES AND USE THEREOF TO TREAT CANCER | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2016-11-17 | — | — | US | disclosed |
| US-20160280652-A1 | ARYLQUINOLINE AND ANALOG COMPOUNDS AND USE THEREOF TO TREAT CANCER | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2016-09-29 | — | — | US | disclosed |
| WO-2015077550-A1 | ARYLQUINOLINE AND ANALOG COMPOUNDS AND USE THEREOF TO TREAT CANCER | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280652-A1 | ARYLQUINOLINE AND ANALOG COMPOUNDS AND USE THEREOF TO TREAT CANCER | CASP4, BAD, BID | TERT 971/4885APP 1086/4885NPC1 2709/4885 |
| US-20160332971-A1 | ARYLQUINOLINE, ARYLQUINOLONE AND ARYLTHIOQUINOLONE DERIVATIVES AND USE THEREOF TO TREAT CANCER | CASP4, PARP14, API5 | TERT 1541/4885APP 2258/4885NPC1 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.